Biotech RadarJobs updated

COMPANY

Novo Nordisk A/S

HQ: Bagsværd, Denmark source · novonordisk.com ↗

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

Location: Bagsværd, Denmark · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Overweight Obesity Type 2 Diabetes Haemophilia A Type 2 Diabetes Mellitus Heart Failure Transthyretin Amyloid Cardiomyopathy (ATTR CM) Cardiovascular Risk Type 2 Diabetes (T2D) Chronic Kidney Disease Type 1 Diabetes Mellitus Born Small for Gestational Age Haemophilia B Noonan Syndrome Obstructive Sleep Apnoea Systemic Inflammation Cardiometabolic Diseases Prediabetes Cardiovascular Disease Dyslipidemia Metabolic Dysfunction-associated Steatotic Liver Disease Diabetes Mellitus Inflammation Severe Postpartum Haemorrhage NNC0487-0111 NNC6019-0001 Zenagamtide Ziltivekimab Norditropin® FlexPro® Nonacog beta pegol Turoctocog alfa pegol Esperoct Norditropin UBT251 Cagrilintide

1,399Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity source ↗
  2. Trial start Phase 3: A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A source ↗
  3. Trial start Phase 1: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medic source ↗
  4. Trial start Phase 1: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medic source ↗
  5. Trial start —: Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany source ↗
  6. Trial start Phase 1: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight source ↗
  7. Trial start Phase 3: A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide source ↗
  8. Trial start Phase 1: A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People source ↗
  9. Trial start Phase 3: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema source ↗
  10. Trial start Phase 1: A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obe source ↗
  11. Trial start Phase 1: A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People source ↗
  12. Trial start Phase 3: AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight source ↗
  13. Trial start —: Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets source ↗
  14. Trial start —: A Retrospective Real-World Cohort Study source ↗
  15. Trial start Phase 1: A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo source ↗
  16. Trial start Phase 2: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes source ↗
  17. Trial start Phase 3: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight source ↗
  18. Trial start Phase 3: AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight source ↗
  19. Trial start Phase 3: AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight source ↗
  20. Trial start Phase 1: A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight source ↗
  21. Trial start Phase 3: AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight source ↗
  22. Trial start Phase 3: A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight source ↗
  23. Trial start —: WEgovy Real World Assessment of Weight Loss in Korea source ↗
  24. Trial start Phase 3: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide source ↗
  25. Trial start Phase 3: CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis source ↗

Showing 25 of 50 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 1,399

RecordTitlePhaseStatusStartPrimary completion
NCT06260709A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin AmyloidosisPhase 2Active, not recruitingFeb 20, 2024Feb 29, 2028 (estimated)
NCT07868354A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationPhase 1Not yet recruitingOct 8, 2026Sep 7, 2028 (estimated)
NCT03972345Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)Not listedEnrolling by invitationJun 21, 2019Jun 30, 2029 (estimated)
NCT03690336Adverse Event Data Collection From External Registries on Nonacog Beta PegolNot listedEnrolling by invitationOct 1, 2018Oct 1, 2027 (estimated)
NCT04682145Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNot listedEnrolling by invitationDec 9, 2020Dec 1, 2026 (estimated)
NCT05621746An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine EsperoctNot listedCompletedNov 23, 2022Apr 30, 2026 (actual)
NCT05308927French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan SyndromeNot listedEnrolling by invitationMar 16, 2022Mar 17, 2028 (estimated)
NCT05726227A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightPhase 3Active, not recruitingJul 7, 2023Oct 15, 2025 (actual)
NCT07571109AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaPhase 3RecruitingMay 5, 2026Jun 26, 2028 (estimated)
NCT07668388A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesPhase 2RecruitingJun 22, 2026Oct 4, 2027 (estimated)
NCT07220759Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePhase 3Active, not recruitingNov 5, 2025May 12, 2027 (estimated)
NCT03811561A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesPhase 3Active, not recruitingMay 8, 2019Nov 7, 2027 (estimated)
NCT07815067A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityPhase 1RecruitingSep 7, 2026Jun 12, 2028 (estimated)
NCT03878446A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayPhase 2Active, not recruitingJul 4, 2019May 5, 2021 (actual)
NCT07861100A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityPhase 3Not yet recruitingOct 26, 2026Sep 16, 2030 (estimated)
NCT07653139Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNot listedEnrolling by invitationSep 25, 2026Dec 26, 2026 (estimated)
NCT06979362A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyPhase 2RecruitingJun 27, 2025Nov 16, 2027 (estimated)
NCT06542874A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesPhase 2CompletedAug 7, 2024Oct 1, 2025 (actual)
NCT07855133A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationPhase 1Not yet recruitingSep 30, 2026Sep 6, 2028 (estimated)
NCT06200207A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationPhase 3Active, not recruitingApr 1, 2024Oct 1, 2026 (estimated)
NCT07757087A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboPhase 1RecruitingAug 3, 2026Sep 18, 2028 (estimated)
NCT05636176A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationPhase 3TerminatedMay 8, 2023Sep 3, 2026 (actual)
NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPhase 3Active, not recruitingNov 1, 2022Oct 30, 2024 (actual)
NCT07797855A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy PeoplePhase 1RecruitingSep 2, 2026Aug 1, 2027 (estimated)
NCT07280221WEgovy Real World Assessment of Weight Loss in KoreaNot listedEnrolling by invitationNov 10, 2025Oct 31, 2027 (estimated)
NCT03596450Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialPhase 4CompletedJul 13, 2018Jun 9, 2022 (actual)
NCT07781371A Retrospective Real-World Cohort StudyNot listedActive, not recruitingAug 20, 2026Nov 2, 2026 (estimated)
NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightPhase 3RecruitingJan 8, 2026Mar 20, 2030 (estimated)
NCT07533175AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 3RecruitingApr 13, 2026Aug 7, 2028 (estimated)
NCT06323174A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePhase 3CompletedMar 19, 2024Oct 1, 2025 (actual)
NCT07850765Real-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsNot listedCompletedAug 28, 2026Aug 31, 2026 (actual)
NCT07525791A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body WeightPhase 1Active, not recruitingApr 7, 2026May 2, 2027 (estimated)
NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termPhase 3Active, not recruitingJun 3, 2025Mar 1, 2027 (estimated)
NCT07817251Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaPhase 3RecruitingSep 16, 2026Jun 9, 2027 (estimated)
NCT06577766A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityPhase 1Active, not recruitingSep 3, 2024Oct 11, 2027 (estimated)
NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPhase 3RecruitingMay 21, 2026Feb 23, 2028 (estimated)
NCT07845578A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightPhase 1Not yet recruitingSep 25, 2026Sep 11, 2027 (estimated)
NCT06813924A Research Study of the Effect of Etavopivat on Other Drugs in Healthy ParticipantsPhase 1CompletedFeb 6, 2025May 27, 2025 (actual)
NCT07720271AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightPhase 3RecruitingAug 31, 2026Jun 27, 2028 (estimated)
NCT05021835ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationPhase 3CompletedAug 30, 2021Jun 9, 2026 (actual)
NCT07668414A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutidePhase 3RecruitingSep 22, 2026Oct 10, 2028 (estimated)
NCT07076199A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPhase 3Active, not recruitingAug 11, 2025Jan 25, 2027 (estimated)
NCT07157423A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaPhase 4RecruitingAug 26, 2025Aug 26, 2027 (estimated)
NCT07160816A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNot listedActive, not recruitingAug 28, 2025Jan 20, 2027 (estimated)
NCT06131372A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPhase 2CompletedApr 1, 2024Sep 24, 2025 (actual)
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPhase 3RecruitingFeb 24, 2026Jun 26, 2029 (estimated)
NCT07207811CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisPhase 3RecruitingOct 2, 2025Jun 29, 2029 (estimated)
NCT07830732A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia APhase 3Not yet recruitingOct 9, 2026Mar 23, 2029 (estimated)
NCT06326047A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesPhase 2CompletedMar 18, 2024Sep 19, 2025 (actual)
NCT07829406A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy PeoplePhase 1Not yet recruitingSep 17, 2026Sep 12, 2027 (estimated)

Connect

See your connections at Novo Nordisk A/S on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback